Targeting Endogenous Mechanisms of Brain Resilience for the Treatment and Prevention of Alzheimer's Disease.

Shanks, H R C; Onuska, K M; Massa, S M; Schmitz, T W; Longo, F M

Shanks, H R C; Onuska, K M; Massa, S M; Schmitz, T W; Longo, F M.

Affiliation

Shanks HRC; Dr. Frank Longo, Department of Neurology and Neurological Sciences, Stanford University, USA, longo@stanford.edu, (650) 724-3172 (office); Dr. Taylor Schmitz, Schulich School of Medicine and Dentistry, Western University, London, Canada, tschmitz@uwo.ca, (519) 661-2111 x80129 (office).

J Prev Alzheimers Dis ; 10(4): 699-705, 2023.

Article in En | MEDLINE | ID: mdl-37874090

Subject(s)

Alzheimer Disease; Animals; Humans; Mice; Alzheimer Disease/drug therapy; Amyloid beta-Peptides/metabolism; Brain/metabolism; Receptor, Nerve Growth Factor/metabolism

Key words

Alzheimer's disease; neuroprotection; p75 neurotrophin receptor; resilience

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Limits: Animals / Humans Language: En Journal: J Prev Alzheimers Dis Year: 2023 Document type: Article Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google